Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study

被引：1
|
作者：
Palazzo, A. [1 ]
Toss, A. [2 ]
Graffeo, R. [3 ]
Fontana, A. [4 ]
Lambertini, M. [5 ]
Pantaleo, F. [4 ]
Perachino, M. [6 ]
Nerone, M. [7 ]
Bianco, N. [8 ]
Vici, P. [9 ]
de Marchis, L. [10 ]
Staropoli, N. [11 ]
Rinaldi, L. [12 ]
Lai, A. [13 ]
Spinelli, G. P. [14 ]
Di Monte, E. [15 ]
Giotta, F. [12 ]
Gennari, A. [16 ]
Cortesi, L. [17 ]
Bria, E. [18 ]
机构：
[1] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol Unit, Comprehens Canc Ctr, Rome, Italy
[2] Azienda Osped Univ Policlin Modena, Dept Oncol & Haematol, Modena, Italy
[3] EOC Osped Reg Lugano Sede Italiano, IOSI, Lugano, Switzerland
[4] AOU Pisana Stabilimento Santa Chiara, Med Oncol, Pisa, Italy
[5] IRCCS AOU San Martino, IST Ist Nazl Ric Cancro, Clin Oncol Med, Genoa, Italy
[6] IRCCS Osped Policlin San Martino, Clin Oncol Dept, Genoa, Italy
[7] EOC Osped Reg Bellinzona & Valli, Ist Oncol Svizzera Italiana IOSI, Reparto Oncol, Bellinzona, Switzerland
[8] IEO Ist Europeo Oncol, Med Senol Dept, Milan, MB, Italy
[9] IRCCS Regina Elena Natl Canc Inst, Phase 4 Clin Study Unit, Rome, Italy
[10] Univ Roma la Sapienza, Fac Med, Radiol Oncol Pathol, Latina, Italy
[11] UMG Univ Magna Graecia Catanzaro, Med Clin & Sperimentale, Catanzaro, Italy
[12] IRCCS, Ist Tumori Bari Giovanni Paolo II, Oncol Inst, Bari, Italy
[13] Mater Olbia Hosp, Dept Oncol, Olbia, Italy
[14] Oncol Univ ASL Aprilia, Dist ASL Latina 1, Aprilia, Italy
[15] Fdn Policlin Univ Agostino Gemelli, IRCCS, Ctr Comprehens Canc, Med Oncol Dept,Unit Med Oncol, Rome, Italy
[16] AOU Maggiore Carita Novara, Dept Translat Med, Novara, Italy
[17] Azienda Osped Univ Policlin Modena, SC Oncol Med, SS Genet Oncol, Modena, Italy
[18] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCCS, Translat Med & Surg, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.654
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
478P
引用
收藏
页码：S382 / S382
页数：1
相关论文
共 50 条
  • [21] Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis
    Gao, Jennifer J.
    Cheng, Joyce
    Prowell, Tatiana M.
    Bloomquist, Erik
    Tang, Shenghui
    Wedam, Suparna B.
    Royce, Melanie
    Krol, Danielle
    Osgood, Christy
    Ison, Gwynn
    Sridhara, Rajeshwari
    Pazdur, Richard
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    LANCET ONCOLOGY, 2021, 22 (11): : 1573 - 1581
  • [22] Alpelisib plus endocrine therapy (ET) in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study
    Juric, Dejan
    Turner, Nicholas
    Prat, Aleix
    Chia, Stephen
    Ciruelos, Eva M.
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Lerebours, Florence
    Bachelot, Thomas
    Balbin, O. Alejandro
    Joshi, Mukta
    Roux, Estelle
    Arce, Christina H.
    Akdere, Murat
    Rugo, Hope S.
    CANCER RESEARCH, 2022, 82 (04)
  • [23] Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor SHR6390 combined with pyrotinib and letrozole in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor positive (HR plus ) metastatic breast cancer (MBC): Phase Ib study results.
    Zhang, Jian
    Meng, Yanchun
    Wang, Biyun
    Wang, Leiping
    Cao, Jun
    Tao, Zhonghua
    Li, Ting
    Yao, Wenqing
    Hu, Xichun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Copy loss enrichment at metastatic disease progression in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer patients treated with endocrine therapy and CDK4/6 inhibition
    Davis, A. A.
    Luo, J.
    Zheng, T.
    Dai, C.
    Suresh, R.
    Ademuyiwa, F. O.
    Rigden, C.
    Clifton, K.
    Weilbaecher, K.
    Frith, A. E.
    Tandra, P.
    Summa, T.
    Thomas, S.
    Peterson, L.
    Wang, X.
    Du, P.
    Jia, S.
    King, B. L.
    Krishnamurthy, J.
    Ma, C. X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S587 - S588
  • [25] HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy
    Zattarin, Emma
    Sposetti, Caterina
    Leporati, Rita
    Mariani, Luigi
    Menichetti, Alice
    Corti, Chiara
    Benvenuti, Chiara
    Fuca, Giovanni
    Lobefaro, Riccardo
    Ligorio, Francesca
    Presti, Daniele
    Provenzano, Leonardo
    Vingiani, Andrea
    Griguolo, Gaia
    Sirico, Marianna
    Bernocchi, Ottavia
    Marra, Antonio
    Zagami, Paola
    Agostinetto, Elisa
    Jacobs, Flavia
    Di Mauro, Pierluigi
    Esposito, Andrea
    Giorgi, Carlo Alberto
    Lalli, Luca
    Boldrini, Laura
    Giachetti, Pier Paolo Maria Berton
    Schianca, Ambra Carnevale
    Guarneri, Valentina
    Pedersini, Rebecca
    Losurdo, Agnese
    Zambelli, Alberto
    Generali, Daniele Giulio
    Curigliano, Giuseppe
    Pruneri, Giancarlo
    de Braud, Filippo
    Dieci, Maria Vittoria
    Vernieri, Claudio
    CANCER RESEARCH, 2023, 83 (05)
  • [26] Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)
    Spring, Laura M.
    Scarpetti, Lauren
    Medford, Arielle J.
    Niemierko, Andrzej
    Comander, Amy
    Mulvey, Therese
    Schnipper, Lowell
    Isakoff, Steven J.
    Moy, Beverly
    Wander, Seth A.
    Shin, Jennifer
    Ephrem, Zanta
    Laposta, Anneke R.
    Denault, Elyssa
    Abraham, Elizabeth
    Calistro, Gayle
    Kalashnikova, Ekaterina
    Rodriguez, Angel
    Liu, Minetta C.
    Aleshin, Alexey
    Peppercorn, Jeffrey
    Ellisen, Leif W.
    Bardia, Aditya
    NPJ BREAST CANCER, 2025, 11 (01)
  • [27] Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer
    Alvarez, Alvaro
    Bernal, Ana M. M.
    Anampa, Jesus
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 198 (01) : 75 - 88
  • [28] Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer
    Alvaro Alvarez
    Ana M. Bernal
    Jesus Anampa
    Breast Cancer Research and Treatment, 2023, 198 : 75 - 88
  • [29] Alpelisib plus letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results
    Rugo, Hope S.
    Lerebours, Florence
    Juric, Dejan
    Turner, Nicholas
    Chia, Stephen
    Drullinsky, Pamela
    Prat, Aleix
    Villanueva Vazquez, Rafael
    Akdere, Murat
    Arce, Christina
    Shen, Yu-Ming
    Ciruelos, Eva
    CANCER RESEARCH, 2021, 81 (04)
  • [30] Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study.
    Telli, Melinda L.
    Litton, Jennifer Keating
    Beck, Joseph Thaddeus
    Jones, Jason M.
    Andersen, Jay
    Mina, Lida A.
    Brig, Raymond
    Danso, Michael A.
    Yuan, Yuan
    Symmans, William Fraser
    Abbattista, Antonello
    Noonan, Kay
    Mata, Marielena
    Laird, Douglas
    Blum, Joanne Lorraine
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345